Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct;34(10):1251-6.
doi: 10.1038/aps.2013.92. Epub 2013 Aug 26.

Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway

Affiliations
Review

Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway

Stavros Apostolakis et al. Acta Pharmacol Sin. 2013 Oct.

Abstract

Atherosclerosis is currently considered an inflammatory disease. Much attention has been focused on the potential role of inflammatory mediators as prognostic/diagnostic markers or therapeutic targets of atherosclerotic cardiovascular disease. CX3CL1 (or fractalkine) is a structurally and functionally unique chemokine with a well documented role in atherosclerosis. In its membrane bound form it promotes the firm adhesion of rolling leucocytes onto the vessel wall, while in its soluble form it serves as a potent chemoattractant for CX3CR1-expressing cells. Additionally, CX3CL1 exerts cytotoxic effects on the endothelium as well as anti-apoptotic and proliferative effects on vascular cells, affecting the context and stability of the atherosclerotic plaque. Studies on animal models have shown that the blockade of the CX3CL1/CX3CR1 pathway ameliorates the severity of atherosclerosis, while genetic epidemiology has confirmed that a genetically-defined less active CX3CL1/CX3CR1 pathway is associated with a reduced risk of atherosclerotic disease in humans. Although several studies support an important pathogenic role of CX3CL1/CX3CR1 in atherogenesis and plaque destabilization, this does not necessarily suggest that this pathway is a suitable therapeutic target or that CX3CL1 can serve as a prognostic/diagnostic biomarker. Further studies on the CX3CL1/CX3CR1 chemokine pathway are clearly warranted to justify the clinical relevance of its role in atherosclerosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CX3CL1 mediated pathways in atherosclerosis. CX3CL1 is synthesized as a membrane-bound molecule with the chemokine domain presented on a mucin-like stalk. Cleavage at the base of this stalk tumor necrosis alpha-converting enzyme, generates a soluble chemokine, which functions as a potent chemoattractant of target cells.
Figure 2
Figure 2
The dual-role of CX3CL1 in atherosclerosis: In its membrane bound form, it promotes the firm adhesion of rolling leucocytes onto the vessel wall (B) promoting sub-endothelial migration (C). In its soluble form, following cleavage by the TNF-alpha converting enzyme, it serves as a potent chemoattractant for CX3CR1-expressing cells (A).

References

    1. Mirzaei M, Truswell AS, Taylor R, Leeder SR. Coronary heart disease epidemics: not all the same. Heart. 2009;95:740–6. - PubMed
    1. European Heart Network. European cardiovascular disease statistics. 2008 edition.
    1. Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med. 1999;340:115–26. - PubMed
    1. Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts) N Engl J Med. 1976;295:420–5. - PubMed
    1. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts) N Engl J Med. 1976;295:369–77. - PubMed